GOLDEN, Colo.--(BUSINESS WIRE)--July 14, 2004--Isonics Corporation (Nasdaq:ISON), a leader in the development of isotopically engineered and nano-structured materials, a supplier of silicon-on-insulator (SOI) wafers to the semiconductor industry and isotopes for life sciences and health care applications, announced today that it is taking immediate action to demand delisting from the Berlin Stock Exchange. The Company's common stock is currently listed on the Berlin Stock Exchange without the Company's permission.

"We believe that the unauthorized listing of Isonics' stock on the Berlin Exchange offers no value to the Company or its shareholders, and are therefore exploring the necessary steps to remove the Company from this exchange," stated Jim Alexander, CEO of Isonics. "There are so many positive things occurring at Isonics: the expansion of our SOI wafer business with the recent acquisition of EnCompass Materials Group, increased interest in Isonics' isotopes for nuclear medicine, increased business in Chemotrade, our German subsidiary, and the expectation of profitability in April of 2005. We strongly believe that the unauthorized listing on the Berlin Exchange will ultimately prove to be inconsequential given the tremendous opportunities ahead for Isonics."

About Isonics Corporation

Isonics Corporation is a world leader in isotopically engineered materials and produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. Isonics also markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Additional information may be obtained at the Company's Web site at http://www.isonics.com.